Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Polychemotherapy in multiple myeloma. The COMPA protocol].

V Vázquez-Villegas, J L Delgado Lamas, F Romero-García

    Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion
    |October 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Treatment of Hodgkin's lymphoma and hematopoietic cell autotransplantation].

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·2002
    Same author

    Nasal angiocentric lymphoma: an entity that should be remembered.

    Annals of plastic surgery·2001
    Same author

    [Usefulness of prothrombin fragment 1 + 2 and fibrin dimer in the detection of hypercoagulation in obstetrical patients with thrombosis risk factors].

    Ginecologia y obstetricia de Mexico·1998
    Same author

    Two different Philadelphia chromosomes in a cell line from an AML-M0 patient.

    Cancer genetics and cytogenetics·1997
    Same author

    [Natural history of paroxysmal nocturnal hemoglobinuria in adolescents,adults, and children: the Mexican experience].

    Sangre·1997
    Same author

    Hairy cell leukemia is infrequent in México and has a geographic distribution.

    American journal of hematology·1996

    This study on multiple myeloma (MM) found that the C.O.M.P.A. regimen achieved high complete remission rates. However, survival outcomes did not significantly differ from other treatment schemes for MM patients.

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Pharmacology

    Context:

    • Multiple myeloma (MM) is a hematologic malignancy.
    • Treatment regimens aim to improve patient response and survival.
    • The C.O.M.P.A. regimen is a combination chemotherapy approach.

    Purpose:

    • To evaluate the efficacy of the C.O.M.P.A. (cyclophosphamide, vincristine, melphalan, prednisone, and adriamycin) regimen in patients with multiple myeloma.
    • To identify prognostic factors influencing treatment response and survival in MM.

    Summary:

    • Ninety-three MM patients received C.O.M.P.A. therapy.
    • Complete remission (CR) was achieved in 65.6% of patients, with a mean survival of 32.3 months.
    • Factors negatively impacting response and survival included low hemoglobin, high serum creatinine, and advanced disease stage (Stage III). Proteinuria affected survival but not response.

    Related Experiment Videos

    Impact:

    • The C.O.M.P.A. regimen demonstrates significant efficacy in achieving complete remissions for multiple myeloma.
    • Prognostic indicators such as hemoglobin, creatinine levels, and disease stage are crucial for predicting patient outcomes.
    • Understanding these factors can help personalize treatment strategies and improve survival for MM patients.